佰仁医疗
(688198)
| 流通市值：147.40亿 | | | 总市值：147.40亿 |
| 流通股本：1.38亿 | | | 总股本：1.38亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 381,722,916.02 | 248,028,217.88 | 100,139,512.37 | 501,879,121.74 |
| 营业收入 | 381,722,916.02 | 248,028,217.88 | 100,139,512.37 | 501,879,121.74 |
| 二、营业总成本 | 305,076,828.91 | 189,298,122.56 | 80,035,115.12 | 362,250,854.74 |
| 营业成本 | 45,175,972.41 | 28,419,837.35 | 14,300,970.48 | 58,524,711.44 |
| 税金及附加 | 6,053,926.54 | 4,299,784.13 | 1,344,071.21 | 4,198,830.33 |
| 销售费用 | 104,736,622.49 | 62,141,524.23 | 23,410,959.55 | 121,961,231.76 |
| 管理费用 | 32,086,194.32 | 21,060,792.38 | 8,399,826.52 | 32,960,162.42 |
| 研发费用 | 117,614,167.28 | 74,131,914 | 33,115,530.01 | 151,441,921.38 |
| 财务费用 | -590,054.13 | -755,729.53 | -536,242.65 | -6,836,002.59 |
| 其中:利息费用 | 916,211.87 | 429,950.77 | 106,564.61 | 462,630.48 |
| 其中:利息收入 | 2,103,823.24 | 1,424,794.99 | 731,930.22 | 7,309,673.95 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 255,394.74 | 8,921.33 | 497,473.03 | 742,302.66 |
| 加:投资收益 | 6,697,085.35 | 4,838,321.34 | 1,981,442.39 | 10,011,207.19 |
| 资产处置收益 | 1,758.65 | 1,753.37 | - | 362.99 |
| 信用减值损失(新) | -923,614.77 | 679,924.75 | 67,144.98 | -2,488,383.41 |
| 其他收益 | 18,449,183.91 | 16,640,381.75 | 14,490,211.75 | 5,326,472.29 |
| 四、营业利润 | 101,125,894.99 | 80,899,397.86 | 37,140,669.4 | 153,220,228.72 |
| 加:营业外收入 | 203,515.53 | 178,511.43 | 34,634.14 | 47,054.01 |
| 减:营业外支出 | 5,955,865.97 | 4,673,951.37 | 2,500,000 | 2,481,067.58 |
| 五、利润总额 | 95,373,544.55 | 76,403,957.92 | 34,675,303.54 | 150,786,215.15 |
| 减:所得税费用 | 12,242,580.61 | 10,944,558.43 | 4,493,024.89 | 18,642,719.46 |
| 六、净利润 | 83,130,963.94 | 65,459,399.49 | 30,182,278.65 | 132,143,495.69 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 83,130,963.94 | 65,459,399.49 | 30,182,278.65 | 132,143,495.69 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 92,696,903.19 | 71,400,619.61 | 32,504,318.17 | 146,330,147.71 |
| 少数股东损益 | -9,565,939.25 | -5,941,220.12 | -2,322,039.52 | -14,186,652.02 |
| 扣除非经常损益后的净利润 | 80,115,232.72 | 61,398,330.64 | 23,058,724.48 | 142,103,787.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.67 | 0.52 | 0.24 | 1.07 |
| (二)稀释每股收益 | 0.67 | 0.52 | 0.24 | 1.07 |
| 八、其他综合收益 | -179,256.27 | -74,321.8 | -32,950.47 | 320,537.92 |
| 归属于母公司股东的其他综合收益 | -179,256.27 | -74,321.8 | -32,950.47 | 320,537.92 |
| 九、综合收益总额 | 82,951,707.67 | 65,385,077.69 | 30,149,328.18 | 132,464,033.61 |
| 归属于母公司股东的综合收益总额 | 92,517,646.92 | 71,326,297.81 | 32,471,367.7 | 146,650,685.63 |
| 归属于少数股东的综合收益总额 | -9,565,939.25 | -5,941,220.12 | -2,322,039.52 | -14,186,652.02 |
| 公告日期 | 2025-10-31 | 2025-08-28 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |